GB1326528A - Method of contraception and compositions used therein - Google Patents

Method of contraception and compositions used therein

Info

Publication number
GB1326528A
GB1326528A GB4376471A GB4376471A GB1326528A GB 1326528 A GB1326528 A GB 1326528A GB 4376471 A GB4376471 A GB 4376471A GB 4376471 A GB4376471 A GB 4376471A GB 1326528 A GB1326528 A GB 1326528A
Authority
GB
United Kingdom
Prior art keywords
phenoxy
acetate
methoxy
pyrrolidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4376471A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richardson Vicks Inc
Original Assignee
Richardson Merrell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Merrell Inc filed Critical Richardson Merrell Inc
Publication of GB1326528A publication Critical patent/GB1326528A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1326528 Contraceptive RICHARDSONMERRELL INC 20 Sept 1971 [5 Oct 1970] 43764/71 Heading A5B Contraception in human females is achieved by the administration of a progestagen (A) and an estrogen antagonising compound (B). They may be administered daily or the compound (A) may be administered at least during some of the days 5 to 28 of the menstrual cycle, compound (B) being administered on at least some of days 10 to 25. Suitable progestagens are: chlormadinone, megestrol acetate, melengestrol acetate, norethindrone and its acetate, norgestrel and its acetate, quingestanol and its acetate, desoxynorethindrone and ethynodiol diacetate. The estrogen antagonising agent is selected from the following (the quantities in parenthesis being the daily dose range): cisclomiphene (0.5-50 mg), 2-[p-(p-methoxy-α- phenylphenethyl) phenoxy]-triethylamine (10- 1000 mg), 1-[2-[p-(α-[p-methoxyphenyl]-#-nitrostyryl) phenoxy] ethyl] pyrrolidine (1 to 100 mg), 2[p-(1, 2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine (1-100 mg), 2-[p-(1, 2- diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine-antiestrogenic isomer (1-100 mg), 2-'[p-(6-methoxy-2-phenylindene - 3 - yl) phenoxy] ethyl pyrrolidine (2-200 mg), dl-13-ethylhydro- 6 -methoxy- 2 -phenyl-1-naphthyl) phenoxy] ethyl] pyrrolidine (2-200 mg), dl-3-ethylgona-1, 3, 5 (10)-triene-3, 16α, 17# triol (1- 100 mg) and compounds of the formula: wherein R is H or COCH 3 and R' is H or CH 3 , and equivalent quantities of pharmaceutically acceptable salts of the base compounds.
GB4376471A 1970-10-05 1971-09-20 Method of contraception and compositions used therein Expired GB1326528A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7825870A 1970-10-05 1970-10-05

Publications (1)

Publication Number Publication Date
GB1326528A true GB1326528A (en) 1973-08-15

Family

ID=22142910

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4376471A Expired GB1326528A (en) 1970-10-05 1971-09-20 Method of contraception and compositions used therein

Country Status (8)

Country Link
AU (1) AU462092B2 (en)
BE (1) BE773518A (en)
CA (1) CA963806A (en)
DE (1) DE2149281A1 (en)
FR (1) FR2110233B1 (en)
GB (1) GB1326528A (en)
IL (1) IL37772A (en)
ZA (1) ZA716118B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2129297A (en) * 1976-09-01 1984-05-16 Bristol Myers Co Post-mastectomy treatment dosage units containing megestrol acetate
WO1999024027A2 (en) * 1997-11-06 1999-05-20 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US20210292272A1 (en) * 2020-03-20 2021-09-23 Apotex Inc. Salts of Zuclomiphene

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2129297A (en) * 1976-09-01 1984-05-16 Bristol Myers Co Post-mastectomy treatment dosage units containing megestrol acetate
WO1999024027A2 (en) * 1997-11-06 1999-05-20 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
WO1999024027A3 (en) * 1997-11-06 1999-07-15 American Home Prod Anti-estrogen plus progestin containing oral contraceptives
JP2001522798A (en) * 1997-11-06 2001-11-20 アメリカン・ホーム・プロダクツ・コーポレイション Oral contraceptive containing antiestrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
AU760540B2 (en) * 1997-11-06 2003-05-15 Wyeth Anti-estrogen plus progestin containing oral contraceptives
US20210292272A1 (en) * 2020-03-20 2021-09-23 Apotex Inc. Salts of Zuclomiphene

Also Published As

Publication number Publication date
AU462092B2 (en) 1975-06-12
FR2110233B1 (en) 1974-09-06
CA963806A (en) 1975-03-04
AU3406071A (en) 1973-04-05
IL37772A (en) 1975-04-25
ZA716118B (en) 1972-05-31
BE773518A (en) 1972-01-31
FR2110233A1 (en) 1972-06-02
DE2149281A1 (en) 1972-04-06
IL37772A0 (en) 1971-11-29

Similar Documents

Publication Publication Date Title
US3969502A (en) Method for contraception by the administration of sequential contraceptive preparations
US5262408A (en) Low estrogen oral contraceptives
US3932635A (en) Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
DE69710896T2 (en) PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES
EP0397823B1 (en) Contraception system and method
US3942641A (en) Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
EP0655916B1 (en) Transdermal application agent containing 3-keto-desogestrel
US4145416A (en) Novel agents and novel methods for treatment of climacteric disturbances
DE69117902T2 (en) Progestogen as the only contraceptive
AU7537987A (en) Combination dosage form for pre-menopausal women
NZ278058A (en) 23 or 24 day contraceptive formulation comprising both an estrogen and a gestagen, administered in constant amounts throughout the 23 or 24 days
SE7416039L (en)
US3795734A (en) Cyclic regimen of hormone administration for contraception
US3755573A (en) Fertility control empoying quinestrol and quingestanol acetate
DE19549264A1 (en) Contraception procedure and kit
GB1459675A (en) Method for the prevention of conception
GB1343595A (en) Oral contraceptive combination
GB1326528A (en) Method of contraception and compositions used therein
GB1462893A (en) Method for fertile breeding control in female bovine
GB1285371A (en) Improvements in or relating to therapeutic methods using prostaglandins
GB1152679A (en) Pharmaceutical and Veterinary Preparations
USRE35724E (en) Contraception system and method
GB1488995A (en) Compositions containing anti-androgenic compounds
GB2165750A (en) Contraceptive synergistic association
IE34308L (en) 11ß, 13ß-DIALKYLGONA-1,3,5(10)-TRIEN-3-OL 3-CYCLOALKYL¹ETHERS

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PLNP Patent lapsed through nonpayment of renewal fees